Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study
Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1013038/full |
| _version_ | 1828107347762872320 |
|---|---|
| author | Yun Lu Qing-qing Yang Lin Zhuo Kun Yang Hao Kou Su-yu Gao Wen Hu Qiao-li Jiang Wen-jing Li Dong-fang Wu Feng Sun Hong Cheng Siyan Zhan Siyan Zhan |
| author_facet | Yun Lu Qing-qing Yang Lin Zhuo Kun Yang Hao Kou Su-yu Gao Wen Hu Qiao-li Jiang Wen-jing Li Dong-fang Wu Feng Sun Hong Cheng Siyan Zhan Siyan Zhan |
| author_sort | Yun Lu |
| collection | DOAJ |
| description | Ambroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 ± 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54–1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients. |
| first_indexed | 2024-04-11T10:29:46Z |
| format | Article |
| id | doaj.art-e3f752083f814baa9e1275a7e03a5a63 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-04-11T10:29:46Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-e3f752083f814baa9e1275a7e03a5a632022-12-22T04:29:28ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2022-10-011310.3389/fmicb.2022.10130381013038Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort studyYun Lu0Qing-qing Yang1Lin Zhuo2Kun Yang3Hao Kou4Su-yu Gao5Wen Hu6Qiao-li Jiang7Wen-jing Li8Dong-fang Wu9Feng Sun10Hong Cheng11Siyan Zhan12Siyan Zhan13Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaDepartment of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, ChinaResearch Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, ChinaAmbroxol is a commonly used mucolytic agent principally used to treat respiratory diseases, which may have a role as adjunctive therapy for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but there is lack of evidence about its effectiveness on coronavirus disease-2019 (COVID-19) patients. To study the association between ambroxol use and clinical outcomes among hospitalized patients of COVID-19 infection. We conducted a multicenter retrospective cohort study involving 3,111 patients with confirmed SARS-CoV-2 infection from three hospitals in Wuhan from 19 December 2019 to 15 April 2020, and the primary outcome was in-hospital mortality. COVID-19 patients were classified into ambroxol and non-ambroxol groups based on the administration of ambroxol during hospitalization. Two analyses including propensity score matching (PSM) to obtain a 1:1 balanced cohort and logistic regression were used to control for confounding factors. The average age of 3,111 patients was 57.55 ± 14.93 years old, 127 of them died during hospitalization, and 924 of them used ambroxol. Treatment with ambroxol did not have a significant effect on in-hospital mortality of COVID-19 patients when compared with non-ambroxol in PSM model after adjusting for confounders (8.0% vs. 3.5%, adjusted OR, 1.03 [95% CI, 0.54–1.97], p = 0.936). Adverse events such as nausea/vomiting, headache, and rash were comparable between the two groups. Our results suggest that the use of ambroxol is not significantly associated with in-hospital mortality in COVID-19 patients, which provides evidence for evaluating the effects of ambroxol on COVID-19 patient outcomes and may be helpful for physicians considering medication alternatives for COVID-19 patients.https://www.frontiersin.org/articles/10.3389/fmicb.2022.1013038/fullambroxolCOVID-19clinical outcomeseffectivenessSARS-CoV-2 |
| spellingShingle | Yun Lu Qing-qing Yang Lin Zhuo Kun Yang Hao Kou Su-yu Gao Wen Hu Qiao-li Jiang Wen-jing Li Dong-fang Wu Feng Sun Hong Cheng Siyan Zhan Siyan Zhan Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study Frontiers in Microbiology ambroxol COVID-19 clinical outcomes effectiveness SARS-CoV-2 |
| title | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
| title_full | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
| title_fullStr | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
| title_full_unstemmed | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
| title_short | Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study |
| title_sort | ambroxol for the treatment of covid 19 among hospitalized patients a multicenter retrospective cohort study |
| topic | ambroxol COVID-19 clinical outcomes effectiveness SARS-CoV-2 |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2022.1013038/full |
| work_keys_str_mv | AT yunlu ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT qingqingyang ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT linzhuo ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT kunyang ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT haokou ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT suyugao ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT wenhu ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT qiaolijiang ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT wenjingli ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT dongfangwu ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT fengsun ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT hongcheng ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT siyanzhan ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy AT siyanzhan ambroxolforthetreatmentofcovid19amonghospitalizedpatientsamulticenterretrospectivecohortstudy |